Skip to main content

ADVERTISEMENT

Mary Anne Dunkin, Contributing Writer

Feature Story
09/15/2021
Peter Sonnenreich, Contributing Writer
Mary Anne Dunkin, Contributing Writer
A number of emerging therapies involving the JAK-STAT pathway are in the pipeline for immune-mediated inflammatory diseases. One particular Janus kinase inhibitor shows potential for atopic dermatitis and vitiligo.
A number of emerging therapies involving the JAK-STAT pathway are in the pipeline for immune-mediated inflammatory diseases. One particular Janus kinase inhibitor shows potential for atopic dermatitis and vitiligo.
A number of emerging therapies...
09/15/2021
The Dermatologist